Who cares whether the study is in Slovenia, as long as it is...

Who cares whether the study is in Slovenia, as long as it is held under strict and internationally recognised trial protocols. The word that impresses me is Proprietorial. This leads to patents and first mover advantage assuming that the trials are successful which I believe have every opportunity of being so. That's the risk discounted in the price right now. You either believe it or leave it. Success leads to credibility which leads to more tests which leads to recognition and then revenue and then further research into other areas. This has to be a LT hold.